Rationale and methodology of the SARAH Trial: Long-term cardiovascular outcomes in patients with resistant hypertension and obstructive sleep apnea (2018)
- Authors:
- Autor USP: DRAGER, LUCIANO FERREIRA - FM
- Unidade: FM
- DOI: 10.1016/j.arbres.2018.03.002
- Subjects: HIPERTENSÃO; APNEIA DO SONO TIPO OBSTRUTIVA; ENSAIO CLÍNICO; SISTEMA CARDIOVASCULAR
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Archivos de bronconeumologia
- ISSN: 0300-2896
- Volume/Número/Paginação/Ano: v. 54, n. 10, p. 518-523, 2018
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
SAPINA-BELTRAN, Esther e DRAGER, Luciano Ferreira. Rationale and methodology of the SARAH Trial: Long-term cardiovascular outcomes in patients with resistant hypertension and obstructive sleep apnea. Archivos de bronconeumologia, v. 54, n. 10, p. 518-523, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.arbres.2018.03.002. Acesso em: 23 jan. 2026. -
APA
Sapina-beltran, E., & Drager, L. F. (2018). Rationale and methodology of the SARAH Trial: Long-term cardiovascular outcomes in patients with resistant hypertension and obstructive sleep apnea. Archivos de bronconeumologia, 54( 10), 518-523. doi:10.1016/j.arbres.2018.03.002 -
NLM
Sapina-beltran E, Drager LF. Rationale and methodology of the SARAH Trial: Long-term cardiovascular outcomes in patients with resistant hypertension and obstructive sleep apnea [Internet]. Archivos de bronconeumologia. 2018 ; 54( 10): 518-523.[citado 2026 jan. 23 ] Available from: https://doi.org/10.1016/j.arbres.2018.03.002 -
Vancouver
Sapina-beltran E, Drager LF. Rationale and methodology of the SARAH Trial: Long-term cardiovascular outcomes in patients with resistant hypertension and obstructive sleep apnea [Internet]. Archivos de bronconeumologia. 2018 ; 54( 10): 518-523.[citado 2026 jan. 23 ] Available from: https://doi.org/10.1016/j.arbres.2018.03.002 - Resistant hypertension: time to consider the best fifth anti-hypertensive treatment
- Does the RYGB common limb length influence hypertension remission and cardiometabolic risk factors? Data from the GATEWAY trial: data from the GATEWAY trial
- Bariatric Surgery for Resistant Hypertension: Working in Progress!
- OSA and cardiometabolic risk: What's the bottom line?
- Are we missing obstructive sleep apnea diagnosis?[Editorial]
- Apneia Obstrutiva do Sono e Aterosclerose: uma abordagem translacional
- Insomnia episodes, new-onset pharmacological treatments, and other sleep disturbances during the COVID-19 pandemic: a nationwide cross-sectional study in Brazilian health care professionals
- OSA and Prognosis After Acute Cardiogenic Pulmonary Edema The OSA-CARE Study
- Obstructive Sleep Apnea and Diabetes Independently Add to Cardiovascular Risk After Coronary Revascularization [Carta]
- Is obstructive sleep apnoea an innocent bystander in the pathophysiology of arterial stiffening? [Editorial]
Informações sobre o DOI: 10.1016/j.arbres.2018.03.002 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
